Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor

Next Previous
X
Search
Trial Profile

A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvecaltamide (Primary)
  • Indications Essential tremor
  • Focus Therapeutic Use
  • Sponsors Cavion; Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 30 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2024 This trial has been completed in Poland (End Date: 30 May 2024), according to European Clinical Trials Database record.
    • 20 Jun 2024 Primary endpoint (Change from Baseline to Week 12 on the TETRAS composite outcome score as summarized by each dose of JZP385 and placebo) has not been met, according to a Jazz Pharmaceuticals plc Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top